CME/CE INFORMATION
RME Webinar Series
Saturday, July 20, 2024 | Virtual Live CME/CE Conference
Broadcast starts at 8:00 AM CT
Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes
Part 1: Understanding the Fundamentals of Pain
Provided by:
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.
Please check with your Board to determine whether this activity will fulfill your state's requirements.
CREDIT AVAILABLE
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Nurses — 1.25 contact hours
- Pharmacists — 1.25 contact hours (0.125 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
LEARNING OBJECTIVES
• Describe the fundamental concepts of pain management, including definitions and mechanisms of pain
• Appropriately assess patients with pain and identify potential risk factors for abuse or addiction
• Describe the different therapeutic options for pain, including nonpharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies
FACULTY
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT
Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Miami, FL
Dana E. King, MD
Clinical Provider
Atrium Health, Wake Forest Baptist
Winston-Salem, NC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - TBD)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speakers' bureau for SCILEX Pharmaceuticals, Inc.
Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Collegium Pharmaceutical, Inc., Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and stock ownership interest in Virpax Pharmaceuticals.
Dana E. King, MD, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes
Part 2: Best Practices for Prescribing Opioids in Primary Care
Provided by:
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.
Please check with your Board to determine whether this activity will fulfill your state's requirements.
CREDIT AVAILABLE
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Nurses — 1.25 contact hours (0.5 contact hour of pharmacotherapy credit)
- Pharmacists — 1.25 contact hours (0.125 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
LEARNING OBJECTIVES
• Appropriately assess patients with pain and identify potential risk factors for abuse or addiction
• Develop an individualized plan of care to safely initiate opioid treatment, while maximizing efficacy and minimizing risks
• Describe the different therapeutic options for pain, including non-pharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies
• Review general and product-specific information about immediate-release (IR) and extended-release/long-acting (ER/LA) opioid analgesics
FACULTY
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT
Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Miami, FL
Dana E. King, MD
Clinical Provider
Atrium Health, Wake Forest Baptist
Winston-Salem, NC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - TBD)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speakers' bureau for SCILEX Pharmaceuticals, Inc.
Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Collegium Pharmaceutical, Inc., Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and stock ownership interest in Virpax Pharmaceuticals.
Dana E. King, MD, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes
Part 3: Opioid Risk Evaluation, Mitigation, and Management
Provided by:
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.
Please check with your Board to determine whether this activity will fulfill your state's requirements.
CREDIT AVAILABLE
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Nurses — 1.25 contact hours
- Pharmacists - 1.25 contact hours (0.125 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
LEARNING OBJECTIVES
• Utilize appropriate methods for monitoring patients using opioid therapy
• Counsel patients about the safe use of opioids, safe disposal, potential for abuse and dependence, and overdose prevention (use of naloxone)
FACULTY
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT
Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Miami, FL
Dana E. King, MD
Clinical Provider
Atrium Health, Wake Forest Baptist
Winston-Salem, NC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - TBD)
Type of Activity: Application
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speakers' bureau for SCILEX Pharmaceuticals, Inc.
Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Collegium Pharmaceutical, Inc., Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and stock ownership interest in Virpax Pharmaceuticals.
Dana E. King, MD, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
- System checker: Must meet all requirements of Digitell Live Events Platform
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
FEE INFORMATION
There is no fee for this educational activity.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification, please contact Talem Health at 800-913-9370 or info@talemhealth.com.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.